Bosun Asset Management LLC Has $1.17 Million Stock Position in Iradimed Corporation (NASDAQ:IRMD)

Bosun Asset Management LLC boosted its stake in Iradimed Corporation (NASDAQ:IRMD - Free Report) by 293.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,300 shares of the medical equipment provider's stock after purchasing an additional 15,890 shares during the quarter. Bosun Asset Management LLC owned about 0.17% of Iradimed worth $1,172,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Iradimed by 113.9% in the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider's stock valued at $1,196,000 after buying an additional 12,657 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Iradimed in the 3rd quarter valued at about $126,000. Principal Financial Group Inc. acquired a new stake in shares of Iradimed in the 3rd quarter valued at about $246,000. JPMorgan Chase & Co. lifted its holdings in shares of Iradimed by 70.2% in the third quarter. JPMorgan Chase & Co. now owns 29,226 shares of the medical equipment provider's stock valued at $1,470,000 after purchasing an additional 12,051 shares in the last quarter. Finally, Albert D Mason Inc. boosted its position in Iradimed by 15.5% during the 4th quarter. Albert D Mason Inc. now owns 16,936 shares of the medical equipment provider's stock worth $931,000 after acquiring an additional 2,277 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Iradimed Stock Down 1.7 %

Shares of Iradimed stock traded down $0.88 on Friday, hitting $51.79. The stock had a trading volume of 24,445 shares, compared to its average volume of 43,511. The stock has a market cap of $658.51 million, a price-to-earnings ratio of 34.53 and a beta of 0.91. Iradimed Corporation has a twelve month low of $41.60 and a twelve month high of $63.29. The business's 50 day moving average is $52.13 and its two-hundred day moving average is $54.33.

Iradimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.05). The firm had revenue of $19.39 million for the quarter, compared to the consensus estimate of $19.09 million. Iradimed had a return on equity of 24.12% and a net margin of 26.26%. As a group, equities analysts predict that Iradimed Corporation will post 1.66 earnings per share for the current fiscal year.

Iradimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 30th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.17 per share. The ex-dividend date is Tuesday, May 20th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.31%. Iradimed's payout ratio is presently 43.87%.

Analyst Ratings Changes

IRMD has been the topic of a number of recent analyst reports. Roth Mkm restated a "buy" rating and set a $72.00 target price (up from $60.00) on shares of Iradimed in a report on Friday, February 14th. StockNews.com upgraded shares of Iradimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday.

Iradimed Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.